Chris Takimoto, MD, Oncology, Menlo Park, CA

ChrisHTakimotoMD

Oncology Menlo Park, CA

Physician

Dr. Takimoto is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Takimoto's full profile

Already have an account?

Education & Training

  • F Edward Hebert School of Medicine - USUHSFELLOWSHIP
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFELLOWSHIP
  • UCSF
    UCSFRESIDENCY
  • Yale University School of Medicine
    Yale University School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2000 - 2022
  • CA State Medical License
    CA State Medical License 1987 - 2021
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
    Chris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
    Chris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
    Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s LymphomaJune 16, 2019 07:16
  • Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid LeukemiaJune 03, 2019 21:57
  • Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin's Lymphoma
    Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin's LymphomaApril 27, 2019 00:43